(WT cohort)
This pipeline uses various statistical tests to identify RPPAs whose expression levels correlated to selected clinical features.
Testing the association between 175 genes and 6 clinical features across 17 samples, statistically thresholded by Q value < 0.05, 2 clinical features related to at least one genes.
-
4 genes correlated to 'LYMPH.NODE.METASTASIS'.
-
ESR1|ER-ALPHA-R-V , PGR|PR-R-V , AR|AR-R-V , TGM2|TRANSGLUTAMINASE-M-V
-
3 genes correlated to 'NEOPLASM.DISEASESTAGE'.
-
ESR1|ER-ALPHA-R-V , PGR|PR-R-V , AR|AR-R-V
-
No genes correlated to 'Time to Death', 'AGE', 'PRIMARY.SITE.OF.DISEASE', and 'GENDER'.
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=0 | ||||
AGE | Spearman correlation test | N=0 | ||||
PRIMARY SITE OF DISEASE | ANOVA test | N=0 | ||||
GENDER | t test | N=0 | ||||
LYMPH NODE METASTASIS | ANOVA test | N=4 | ||||
NEOPLASM DISEASESTAGE | ANOVA test | N=3 |
Time to Death | Duration (Months) | 9.7-131.1 (median=47.4) |
censored | N = 6 | |
death | N = 11 | |
Significant markers | N = 0 |
AGE | Mean (SD) | 57.29 (13) |
Significant markers | N = 0 |
PRIMARY.SITE.OF.DISEASE | Labels | N |
DISTANT METASTASIS | 3 | |
REGIONAL CUTANEOUS OR SUBCUTANEOUS TISSUE (INCLUDES SATELLITE AND IN-TRANSIT METASTASIS) | 3 | |
REGIONAL LYMPH NODE | 11 | |
Significant markers | N = 0 |
GENDER | Labels | N |
FEMALE | 9 | |
MALE | 8 | |
Significant markers | N = 0 |
LYMPH.NODE.METASTASIS | Labels | N |
N0 | 9 | |
N1 | 1 | |
N1A | 1 | |
N1B | 2 | |
N2B | 1 | |
N3 | 1 | |
Significant markers | N = 4 |
ANOVA_P | Q | |
---|---|---|
ESR1|ER-ALPHA-R-V | 8.581e-10 | 1.5e-07 |
PGR|PR-R-V | 1.886e-08 | 3.28e-06 |
AR|AR-R-V | 2.503e-08 | 4.33e-06 |
TGM2|TRANSGLUTAMINASE-M-V | 3.471e-06 | 0.000597 |
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE I | 4 | |
STAGE IA | 1 | |
STAGE II | 1 | |
STAGE IIB | 1 | |
STAGE IIC | 2 | |
STAGE III | 1 | |
STAGE IIIA | 1 | |
STAGE IIIB | 1 | |
STAGE IIIC | 2 | |
Significant markers | N = 3 |
ANOVA_P | Q | |
---|---|---|
ESR1|ER-ALPHA-R-V | 2.232e-06 | 0.000391 |
PGR|PR-R-V | 9.282e-06 | 0.00162 |
AR|AR-R-V | 0.000103 | 0.0178 |
-
Expresson data file = SKCM-WT.rppa.txt
-
Clinical data file = SKCM-WT.clin.merged.picked.txt
-
Number of patients = 17
-
Number of genes = 175
-
Number of clinical features = 6
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.